H.C. Wainwright lowered the firm’s price target on CorMedix (CRMD) to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations have been reset following the updated 2026-2027 DefenCath guidance. CorMedix has entered the next phase of the story where clinical execution now matters more than commercial execution, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix price target lowered to $13 from $22 at RBC Capital
- P/E Steals: 3 Overlooked Stocks Ready to Surge Over 100% in 2026
- Cormedix: Near-Term Reimbursement Headwinds but Compelling Long-Term Upside Supports Buy Rating and $18 Target
- Cormedix: Market Overreaction to 2026 Guidance Creates Undervalued Buy Opportunity
- CorMedix price target lowered to $16 from $20 at Truist